SCHEMBL5162445

SCHEMBL5162445

CCCCC(CC)COC(=O)CC(=O)c1cc2ccccc2cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
CYP3A4 P08684 3/20 0.50
CA2 P00918 1/20 0.50
LMNA P02545 3/20 0.46
TSHR P16473 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
ATM Q13315 1/20 0.46
MAPK1 P28482 3/20 0.46
PRSS1 P07477 1/20 0.46
PRSS2 P07478 1/20 0.46
PRSS3 P35030 1/20 0.46
HSD17B10 Q99714 1/20 0.41
RECQL P46063 1/20 0.40
CTSK P43235 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
EGLN1 Q9GZT9 1/20 0.37
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5158734 0.82 ALDH1A1 (0.54) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5160010 0.81 ALDH1A1 (0.51) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5162416 0.81 ALDH1A1 (0.48) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5161426 0.80 GABRP (0.46) ALDH1A1LMNAMAPK1HDAC3HDAC1
SCHEMBL5162808 0.78 ALDH1A1 (0.50) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL1201268 0.78 ALDH1A1 (0.60) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5160657 0.77 CYP3A4 (0.55) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5160376 0.76 CYP3A4 (0.49) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5162754 0.76 ALDH1A1 (0.50) ALDH1A1CYP3A4CA2LMNATSHR
SCHEMBL5160628 0.76 ALDH1A1 (0.50) ALDH1A1CYP3A4CA2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ALDH1A1 273/4885CYP3A4 7/4885CA2 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.